Estimating The Economic and Clinical Benefits of Mirabegron Versus Antimuscarinics for The Treatment of Overactive Bladder (OAB) in The United Kingdom (UK)
Abstract
Authors
J Nazir M Berling C McCrea F Fatoye Z Hakimi A Wagg